US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Capricor Therapeutics, Inc. - Common Stock (NQ:CAPR)

8.100 +0.350 (+4.52%)
Delayed Quote Updated: 4:00 PM EDT, Oct 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Capricor Therapeutics, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >
News headline image
CAPR Stock Surged 17% Today — What’s Fueling The Rally? ↗
The FDA has lifted a previous Complete Response Letter and resumed review of the company’s Biologics License Application for Deramiocel. 
Via Stocktwits
News headline image
CAPR Stock In Spotlight As Investors Eye Next Week’s DMD Trial Data Showing Muscle And Cardiac Gains ↗
The FDA review of Deramiocel remains ongoing and could eventually lead to the assignment of a new PDUFA decision date. 
Via Stocktwits
News headline image
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? ↗
Capricor is approaching a regulatory filing timeline and earnings, while Sarepta heads into results under legal and safety pressure. 
Via Stocktwits
News headline image
Nasdaq, S&P 500 Futures Fall On Tariff, Iran Tensions: Why NVDA, NFLX, HON, IBRX, MLTX Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment on SPY and QQQ has been ‘bearish’. 
Via Stocktwits
Topics Artificial Intelligence ETFs Government
‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17% ↗
Via Stocktwits
Capricor Therapeutics Stock Jumps After-Hours As Retail Cheers Fresh FDA Attempt After Duchenne Therapy Rejection ↗
Via Stocktwits
News headline image
CAPR Stock Rallied Nearly 30% So Far This Week — Here’s The February FDA Catalyst Investors Are Betting On ↗
Shares jumped over 14% on Thursday to their highest level and strongest session since December, when the company reported strong DMD trial results. 
Via Stocktwits
News headline image
CAPR Stock Slides After FDA Requests More Data For Genetic Disorder Therapy — What Does Retail Think? ↗
The FDA has formally requested the full HOPE-3 clinical study report (CSR) and supporting data, Capricor said on Tuesday. 
Via Stocktwits
News headline image
Here's Why This Biotechnology Skyrocketed by 439% in December ↗
A successful Phase 3 trial and a public offeringof stock boosted prospects for this company to receive approval for an exciting new treatment. 
Via The Motley Fool
News headline image
On Friday, there are stocks with unusual volume. Let's take a look. ↗
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill
Tesla Chair Declares Start Of 'Whole New Book' As Musk's 423 Million Share Award Is Locked In — All Hope Pinned On Robotaxi, Optimus ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 10, 2025 ↗
 
Via Benzinga
News headline image
Preview: Capricor Therapeutics's Earnings ↗
 
Via Benzinga
Capricor Stock Rises Pre-Market Over Fresh Hopes of Deramiocel Approval In Treating Genetic Disorder ↗
Via Stocktwits
News headline image
Let's take a look at the stocks that are in motion in today's session. ↗
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Capricor’s Red-Hot Rally Has Wall Street And Retail Hooked — And Fresh DMD Data Could Keep Fueling The Fire ↗
DMD patients may soon gain access to a therapy that not only targets muscle decline but also tackles heart complications — the leading cause of death in this rare genetic disorder. 
Via Stocktwits
News headline image
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 3, 2025 – Capricor Therapeutics (NASDAQ: CAPR) has sent shockwaves through the biotech sector today, witnessing an astonishing 535% surge in its stock price, propelling the company to an... 
Via MarketMinute
News headline image
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win ↗
Capricor’s positive HOPE-3 results prompted Shkreli to call his short thesis a “bad call” after the therapy showed statistically significant skeletal and cardiac benefits. 
Via Stocktwits
News headline image
Why Did Capricor Therapeutics Stock Skyrocket Today? ↗
The HOPE-3 study, involving 106 participants across 20 U.S. centres, delivered strong signals of benefit for muscle and heart function. 
Via Stocktwits
News headline image
Get insights into the top gainers and losers of Wednesday's pre-market session. ↗
Discover the top movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
News headline image
Nasdaq, S&P 500 Futures Point To Steady Open: Why CAPR, MRVL, AEO, GTLB, CRWD Are On Traders' Radar ↗
After a volatile start to the week, markets are showing signs of stabilization. 
Via Stocktwits
Topics Artificial Intelligence ETFs Economy
News headline image
Capricor Therapeutics Stock Sparks Retail Frenzy As Traders Hail ‘Best Data’ Ahead Of DMD Data Readout ↗
Capricor said in early November that it expects to announce results from the HOPE-3 trial in the coming weeks. 
Via Stocktwits
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
News headline image
Top movers in Monday's session ↗
Intrigued by the market activity in the middle of the day on Monday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill
News headline image
Top Stocks With Earnings This Week: Plug, Oklo, Circle And More ↗
Here's a look at this week's earnings reports that are most likely to be watched by retail investors, including Oklo, Plug and Circle. 
Via Benzinga
News headline image
Capricor Therapeutics Stock Becomes Talk Of Retail Town On DMD Study; Retail Sees New Hope After Sarepta Setback ↗
Capricor’s peer-reviewed publication in Biomedicines reinforced the scientific foundation of its Duchenne therapy Deramiocel, highlighting its anti-fibrotic mechanism and consistent potency. 
Via Stocktwits
News headline image
CAPRICOR INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Why Capricor Therapeutics Stock Is Surging Today ↗
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its rare disease therapeutics. 
Via Benzinga
News headline image
Gapping stocks in Thursday's session ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday. 
Via Chartmill
News headline image
CAPRICOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
19 20 Next >